Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Phase 1 Completed 31 enrolled Amgen Merck Sharp & Dohme LLC · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

The primary objective of the study is to determine the maximum tolerated dose (MTD) of blinatumomab in combination with pembrolizumab in adults with relapsed or refractory (r/r) DLBCL.

Timeline

Start: 2018-03-16
Primary completion: 2020-11-06
Completion: 2023-08-14

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Blinatumomab	Monoclonal antibody	28 ug	Intravenous
Subject	Blinatumomab	Monoclonal antibody	56 ug	Intravenous
Subject	Blinatumomab	Monoclonal antibody	112 ug	Intravenous
Subject	Pembrolizumab	Monoclonal antibody	200 mg	Intravenous

Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Summary

Timeline

Drugs

Indications